Drug Interactions between deferasirox and doxorubicin
This report displays the potential drug interactions for the following 2 drugs:
- deferasirox
- doxorubicin
Interactions between your drugs
DOXOrubicin deferasirox
Applies to: doxorubicin and deferasirox
GENERALLY AVOID: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme. One group of investigators reported a nearly 60% increase in the plasma clearance of doxorubicin in patients receiving barbiturates compared to those not receiving barbiturates. Reduced therapeutic effects of doxorubicin may occur.
MANAGEMENT: Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.
References
- Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR (1982) "Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects." Clin Pharmacol Ther, 31, p. 263
- (2001) "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn
- (2001) "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Drug and food interactions
deferasirox food
Applies to: deferasirox
ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.
MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.
References
- (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.